Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03630211 · ClinicalTrials.gov registry record · Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

A Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Paul Szabolcs.

Recruiting
Registry status
Phase 2
Development phase
8
Enrollment target
3
Study locations

NCT03630211: Recruiting Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Paul Szabolcs.

NCT03630211 is a Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 8 participants, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03630211, a Phase 2 study of Pulmonary Hypertension and Interstitial Lung Disease, is actively recruiting participants, sponsored by Paul Szabolcs.

RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

Primary Outcome

Safety will be determined by monitoring for death of any cause, regimen-related toxicities, and severe or life-threatening infections.

Conditions Studied

Pulmonary Hypertension Interstitial Lung Disease Systemic Sclerosis Diffuse Sclerosis Systemic

Interventions

  • DRUG Cyclophosphamide
  • DRUG Alemtuzumab
  • DRUG Mesna
  • DRUG Rituximab
  • DRUG Thiotepa

Study Locations (3)

Pennsylvania

  • Children's Hospital of Pittsburgh of UPMC - Pittsburgh
  • University of Pittsburgh Medical Center - Pittsburgh
  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2018-07-31
Est. Completion 2026-08-01
Phase Phase 2
Paul Szabolcs

7 total trials

What NCT03630211 shows while recruiting

NCT03630211 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 614-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT03630211 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03630211 about?

NCT03630211 is a clinical study titled "Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis". The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

What is the current status of trial NCT03630211?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-07-31. Estimated completion is 2026-08-01.

What conditions does trial NCT03630211 study?

This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease, Systemic Sclerosis, Diffuse Sclerosis Systemic.

What interventions are being tested in trial NCT03630211?

The interventions under investigation include: Cyclophosphamide (DRUG), Alemtuzumab (DRUG), Mesna (DRUG), Rituximab (DRUG), Thiotepa (DRUG).

Who is sponsoring clinical trial NCT03630211?

This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03630211 being conducted?

This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03630211's enrollment target sits among peer trials

8 70th of 72 higher than 2 of 72 other Pulmonary Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03630211

Source: ClinicalTrials.gov NCT03630211, the US trial registry maintained by the National Library of Medicine. NCT03630211 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.